Boston Scientific (NYSE:BSX) posts better-than-expected sales in Q3 2026 but quarterly revenue guidance misses expectations

Boston Scientific reported Q3 2026 revenue of $5.14 billion, exceeding estimates by 1.4%, but missed revenue and EPS guidance for Q4 2026. Adjusted EPS was in line at $0.73. Operating margin declined to 16.1% from 20.7% year-over-year, and organic revenue grew 1.5%.

Original reporting
Published Oct 28, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Boston Scientific (NYSE:BSX) posts better-than-expected sales in Q3 2026 but quarterly revenue guidance misses expectations — source image
Decision brief

The 30-second read

$BSXNeutralMed
01

Why it matters

Traders will likely focus on the forward guidance gap: Q4 revenue midpoint of $5.18B versus $5.42B consensus, and a full-year adjusted EPS midpoint cut to $3.17.

02

Market read

A clear earnings-guidance setup with a Q3 beat but weaker forward revenue and lowered full-year EPS guidance, plus margin compression.

03

What to watch

Operating margin fell to 16.1% from 20.7% a year ago, which may reflect mix or cost pressures that could persist into subsequent quarters if not addressed.

Relevance 8/10Novelty 7/10Timing: pre-market/early trading after the Q3 results and Q4 guidance release

Background

The article summarizes Boston Scientific’s Q3 2026 results versus analyst consensus and highlights guidance changes for Q4 2026 revenue and full-year adjusted EPS.

Company-level read

Ticker impact

$BSXNeutralHigh confidence
Context

Boston Scientific reported Q3 2026 revenue of $5.14B vs $5.07B consensus, but guided Q4 revenue to $5.18B below $5.42B expectations.

Expected impact

Likely near-term pressure as the market reprices the forward revenue and EPS outlook despite the Q3 beat.

Evidence & confidence

The article’s decision-relevant new facts are the Q4 revenue midpoint guidance miss and the full-year adjusted EPS guidance cut, both directly tied to BSX’s forward earnings power.

Market effects

Medical device peers may see read-across on demand durability and pricing, given BSX’s organic growth beat paired with weaker forward guidance.

Limited, as this is company-specific guidance rather than a broad macro release.

Low, since the disclosed catalysts are tied to BSX’s own quarterly and full-year outlook.

Counterpoint

The Q3 revenue and organic growth beats plus in-line adjusted EPS could indicate the guidance miss is temporary, driven by timing rather than underlying demand weakness.

Key entities

  • Boston Scientific

    US-listed medical device company reporting Q3 2026 results and issuing Q4 revenue and full-year adjusted EPS guidance.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.